The U.S. Food and Drug Administration has approved Yuvezzi (carbachol and brimonidine tartrate) ophthalmic solution 2.75%/0.1 ...
Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA ...
The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...
The US Food and Drug Administration has approved a landmark eye drop that uses a combined dose of medication to restore ...
Tenpoint Therapeutics is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, ...
Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to ...
The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...
LONDON & SEATTLE, June 03, 2025--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd. ("Tenpoint"), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate ...
The gradual loss of near vision that is a natural part of aging can be addressed by glasses, contact lenses, or even surgical procedures. A presbyopia eye drop developed by Tenpoint Therapeutics now ...
Eye-focused biotechs Tenpoint Therapeutics and Visus Therapeutics are joining forces, setting their sights on filing a new drug approval application next year for a presbyopia-correcting eye drop.
YUVEZZI (TM) (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results